Journal of Clinical Pharmacology

Papers
(The H4-Index of Journal of Clinical Pharmacology is 19. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Incidence of Antiseizure Medication–Induced Severe Cutaneous Adverse Reactions in Malaysia69
50
Pharmacokinetics of Tacrolimus in Pregnant Solid‐Organ Transplant Recipients: A Retrospective Study45
Population Pharmacokinetic and Pharmacodynamic of Atorvastatin in Chinese Lung Transplant Recipients45
Extrapolation of Adult Efficacy Data to Pediatric Systemic Lupus Erythematosus: Evaluating Similarities in Exposure–Response36
The Nocebo Response in Pharmacologic Treatments of Primary Headache: A Systematic Review and Meta‐Analysis32
30
Neurological Immune‐Related Adverse Events After COVID‐19 Vaccination: A Systematic Review28
Meta‐Analysis of Noncompartmental Pharmacokinetic Parameters of Ertugliflozin to Evaluate Dose Proportionality and UGT1A9 Polymorphism Effect on Exposure27
Evaluation of the Pharmacokinetics of Dapagliflozin in Patients With Chronic Kidney Disease With or Without Type 2 Diabetes Mellitus26
The Effects of the Early and Late Phases of Septic Shock on the Population Pharmacokinetics of Vancomycin24
Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration23
Reassessing the Pediatric Dosing Recommendations for Unfractionated Heparin Using Real‐World Data: A Pharmacokinetic–Pharmacodynamic Modeling Approach22
Improving Racial and Ethnic Equity in Clinical Trials Enrolling Pregnant and Lactating Individuals22
Clinical Lactation Studies of Neuropsychiatric Medications: Clinical Pharmacology and Labeling Considerations22
22
Pharmacokinetics and Pharmacodynamics of GalNAc‐Conjugated siRNAs22
Protecting Mothers and Babies Through Research21
20
Evaluation of the Pharmacokinetic Drug Interaction of Capmatinib With Itraconazole and Rifampicin and Potential Impact on Renal Transporters in Healthy Subjects19
0.057880163192749